MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-27-2025
OrganiGram Holdings Market Cap 2011-2026 | OGI
As of March 24, 2026 OrganiGram Holdings has a market cap of $ 402 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap OrganiGram Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 382 M | 356 M | 365 M | - | - | 75.6 M | - | 3.89 M | 41.7 M | 176 M | 170 M |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 382 M | 3.89 M | 196 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
915 M | $ 3.28 | -0.91 % | $ 86.3 M |  Canada |
 |
China Pharma Holdings
CPHI
|
4.54 M | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
3.63 B | $ 2.54 | 0.79 % | $ 1.33 B | Canada |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
139 M | $ 8.03 | -0.25 % | $ 411 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.17 | 3.77 % | $ 44.6 M | USA |
 |
Bausch Health Companies
BHC
|
3.38 B | $ 4.97 | -2.74 % | $ 1.81 B | Canada |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 22.73 | 0.35 % | $ 1.05 B | USA |
 |
Harrow Health
HROW
|
1.93 B | $ 35.35 | 3.96 % | $ 1.3 B | USA |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
271 M | $ 4.62 | -1.39 % | $ 298 M | USA |
 |
Rockwell Medical
RMTI
|
35.5 M | $ 1.05 | 2.94 % | $ 24.5 M | USA |
 |
Solid Biosciences
SLDB
|
623 M | $ 6.79 | -4.97 % | $ 594 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Sundial Growers
SNDL
|
889 K | $ 1.36 | - | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.34 | -8.24 % | $ 2.9 M | USA |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 6.08 | 3.67 % | $ 240 M | USA |
 |
Tilray
TLRY
|
1.19 B | $ 6.43 | -0.31 % | $ 3.97 B | Canada |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
108 M | $ 2.3 | - | $ 310 M | USA |
 |
Jupiter Wellness
JUPW
|
82.8 M | - | - | $ 33.6 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 13.44 | 1.09 % | $ 16.1 B | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 0.87 | -0.59 % | $ 43.4 M | USA |
 |
TherapeuticsMD
TXMD
|
23.9 M | $ 2.29 | -1.07 % | $ 23.9 M | USA |
 |
cbdMD
YCBD
|
1.68 M | $ 0.77 | 1.21 % | $ 3.32 M | USA |
 |
Organogenesis Holdings
ORGO
|
415 M | $ 2.4 | -2.83 % | $ 316 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
1.96 B | $ 9.74 | 1.78 % | $ 1.35 B | USA |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 0.95 | -1.5 % | $ 102 M | Canada |
 |
Assertio Holdings
ASRT
|
75.4 M | $ 16.05 | 14.64 % | $ 103 M | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |